Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers

Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug metabolism and disposition 2013-01, Vol.41 (1), p.224-229
Hauptverfasser: Cabaleiro, Teresa, Román, Manuel, Ochoa, Dolores, Talegón, María, Prieto-Pérez, Rocío, Wojnicz, Aneta, López-Rodríguez, Rosario, Novalbos, Jesús, Abad-Santos, Francisco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 229
container_issue 1
container_start_page 224
container_title Drug metabolism and disposition
container_volume 41
creator Cabaleiro, Teresa
Román, Manuel
Ochoa, Dolores
Talegón, María
Prieto-Pérez, Rocío
Wojnicz, Aneta
López-Rodríguez, Rosario
Novalbos, Jesús
Abad-Santos, Francisco
description Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telmisartan. The study population comprised 246 healthy volunteers from seven single-dose clinical trials: 64 from two candesartan studies, 43 from a telmisartan study, 36 from a losartan study, and 103 from three valsartan studies. DNA was extracted from blood samples and single-nucleotide polymorphisms in the CYP2C8 (CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP2C8*5) and CYP2C9 (CYP2C9*2, CYP2C9*3) genes were evaluated using real-time polymerase chain reaction. Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01). CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05). CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001). These results suggest that genotypes for CYP2C9 and CYP2C8 are relevant to the pharmacokinetics of losartan and valsartan, respectively, but not the pharmacokinetics of candesartan or telmisartan.
doi_str_mv 10.1124/dmd.112.046292
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273402189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273402189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-549733911ab586dcf9a8c343de7bcd1b3e8687ec05f2007ce7f927213f0ab6b13</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EoqWwMiKPDE3xtfPyiKrykCrBABJMkePcUNMkDnYK9Afwv0kfMN3vSuec4SPkHNgEgIdXRV1sYMLCmEt-QIYQcQgYky-HZNgfFsgoigfkxPt3xiAMhTwmAy4AUsHTIfmZfapqpTpjG2pL2i2QOqy2v1-YlubYfSE21OP3mLa2WtfWtQvja09NQ6evj3yaUtUUO5TjLbcL5Wql7dI02BntN8uqeTO2w8b3NYca2846mldWL9H5U3JUqsrj2f6OyPPN7Gl6F8wfbu-n1_NAixi6IAplIoQEUHmUxoUupUq1CEWBSa4LyAWmcZqgZlHJGUs0JqXkCQdRMpXHOYgRudztts5-rNB3WW28xqpSDdqVz4AnImQcUtlHJ7uodtZ7h2XWOlMrt86AZRv1Wa9-A9lOfV-42G-v8hqL__ifa_ELkDGAiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273402189</pqid></control><display><type>article</type><title>Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Cabaleiro, Teresa ; Román, Manuel ; Ochoa, Dolores ; Talegón, María ; Prieto-Pérez, Rocío ; Wojnicz, Aneta ; López-Rodríguez, Rosario ; Novalbos, Jesús ; Abad-Santos, Francisco</creator><creatorcontrib>Cabaleiro, Teresa ; Román, Manuel ; Ochoa, Dolores ; Talegón, María ; Prieto-Pérez, Rocío ; Wojnicz, Aneta ; López-Rodríguez, Rosario ; Novalbos, Jesús ; Abad-Santos, Francisco</creatorcontrib><description>Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telmisartan. The study population comprised 246 healthy volunteers from seven single-dose clinical trials: 64 from two candesartan studies, 43 from a telmisartan study, 36 from a losartan study, and 103 from three valsartan studies. DNA was extracted from blood samples and single-nucleotide polymorphisms in the CYP2C8 (CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP2C8*5) and CYP2C9 (CYP2C9*2, CYP2C9*3) genes were evaluated using real-time polymerase chain reaction. Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01). CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05). CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001). These results suggest that genotypes for CYP2C9 and CYP2C8 are relevant to the pharmacokinetics of losartan and valsartan, respectively, but not the pharmacokinetics of candesartan or telmisartan.</description><identifier>ISSN: 0090-9556</identifier><identifier>EISSN: 1521-009X</identifier><identifier>DOI: 10.1124/dmd.112.046292</identifier><identifier>PMID: 23118328</identifier><language>eng</language><publisher>United States</publisher><subject>Alleles ; Angiotensin Receptor Antagonists - pharmacokinetics ; Aryl Hydrocarbon Hydroxylases - genetics ; Cytochrome P-450 CYP2C8 ; Cytochrome P-450 CYP2C9 ; Female ; Half-Life ; Humans ; Male ; Polymorphism, Genetic ; Reference Values ; Sex Factors</subject><ispartof>Drug metabolism and disposition, 2013-01, Vol.41 (1), p.224-229</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-549733911ab586dcf9a8c343de7bcd1b3e8687ec05f2007ce7f927213f0ab6b13</citedby><cites>FETCH-LOGICAL-c361t-549733911ab586dcf9a8c343de7bcd1b3e8687ec05f2007ce7f927213f0ab6b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23118328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cabaleiro, Teresa</creatorcontrib><creatorcontrib>Román, Manuel</creatorcontrib><creatorcontrib>Ochoa, Dolores</creatorcontrib><creatorcontrib>Talegón, María</creatorcontrib><creatorcontrib>Prieto-Pérez, Rocío</creatorcontrib><creatorcontrib>Wojnicz, Aneta</creatorcontrib><creatorcontrib>López-Rodríguez, Rosario</creatorcontrib><creatorcontrib>Novalbos, Jesús</creatorcontrib><creatorcontrib>Abad-Santos, Francisco</creatorcontrib><title>Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers</title><title>Drug metabolism and disposition</title><addtitle>Drug Metab Dispos</addtitle><description>Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telmisartan. The study population comprised 246 healthy volunteers from seven single-dose clinical trials: 64 from two candesartan studies, 43 from a telmisartan study, 36 from a losartan study, and 103 from three valsartan studies. DNA was extracted from blood samples and single-nucleotide polymorphisms in the CYP2C8 (CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP2C8*5) and CYP2C9 (CYP2C9*2, CYP2C9*3) genes were evaluated using real-time polymerase chain reaction. Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01). CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05). CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001). These results suggest that genotypes for CYP2C9 and CYP2C8 are relevant to the pharmacokinetics of losartan and valsartan, respectively, but not the pharmacokinetics of candesartan or telmisartan.</description><subject>Alleles</subject><subject>Angiotensin Receptor Antagonists - pharmacokinetics</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Cytochrome P-450 CYP2C8</subject><subject>Cytochrome P-450 CYP2C9</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Male</subject><subject>Polymorphism, Genetic</subject><subject>Reference Values</subject><subject>Sex Factors</subject><issn>0090-9556</issn><issn>1521-009X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EoqWwMiKPDE3xtfPyiKrykCrBABJMkePcUNMkDnYK9Afwv0kfMN3vSuec4SPkHNgEgIdXRV1sYMLCmEt-QIYQcQgYky-HZNgfFsgoigfkxPt3xiAMhTwmAy4AUsHTIfmZfapqpTpjG2pL2i2QOqy2v1-YlubYfSE21OP3mLa2WtfWtQvja09NQ6evj3yaUtUUO5TjLbcL5Wql7dI02BntN8uqeTO2w8b3NYca2846mldWL9H5U3JUqsrj2f6OyPPN7Gl6F8wfbu-n1_NAixi6IAplIoQEUHmUxoUupUq1CEWBSa4LyAWmcZqgZlHJGUs0JqXkCQdRMpXHOYgRudztts5-rNB3WW28xqpSDdqVz4AnImQcUtlHJ7uodtZ7h2XWOlMrt86AZRv1Wa9-A9lOfV-42G-v8hqL__ifa_ELkDGAiA</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Cabaleiro, Teresa</creator><creator>Román, Manuel</creator><creator>Ochoa, Dolores</creator><creator>Talegón, María</creator><creator>Prieto-Pérez, Rocío</creator><creator>Wojnicz, Aneta</creator><creator>López-Rodríguez, Rosario</creator><creator>Novalbos, Jesús</creator><creator>Abad-Santos, Francisco</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers</title><author>Cabaleiro, Teresa ; Román, Manuel ; Ochoa, Dolores ; Talegón, María ; Prieto-Pérez, Rocío ; Wojnicz, Aneta ; López-Rodríguez, Rosario ; Novalbos, Jesús ; Abad-Santos, Francisco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-549733911ab586dcf9a8c343de7bcd1b3e8687ec05f2007ce7f927213f0ab6b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alleles</topic><topic>Angiotensin Receptor Antagonists - pharmacokinetics</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Cytochrome P-450 CYP2C8</topic><topic>Cytochrome P-450 CYP2C9</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Male</topic><topic>Polymorphism, Genetic</topic><topic>Reference Values</topic><topic>Sex Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cabaleiro, Teresa</creatorcontrib><creatorcontrib>Román, Manuel</creatorcontrib><creatorcontrib>Ochoa, Dolores</creatorcontrib><creatorcontrib>Talegón, María</creatorcontrib><creatorcontrib>Prieto-Pérez, Rocío</creatorcontrib><creatorcontrib>Wojnicz, Aneta</creatorcontrib><creatorcontrib>López-Rodríguez, Rosario</creatorcontrib><creatorcontrib>Novalbos, Jesús</creatorcontrib><creatorcontrib>Abad-Santos, Francisco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug metabolism and disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cabaleiro, Teresa</au><au>Román, Manuel</au><au>Ochoa, Dolores</au><au>Talegón, María</au><au>Prieto-Pérez, Rocío</au><au>Wojnicz, Aneta</au><au>López-Rodríguez, Rosario</au><au>Novalbos, Jesús</au><au>Abad-Santos, Francisco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers</atitle><jtitle>Drug metabolism and disposition</jtitle><addtitle>Drug Metab Dispos</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>41</volume><issue>1</issue><spage>224</spage><epage>229</epage><pages>224-229</pages><issn>0090-9556</issn><eissn>1521-009X</eissn><abstract>Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telmisartan. The study population comprised 246 healthy volunteers from seven single-dose clinical trials: 64 from two candesartan studies, 43 from a telmisartan study, 36 from a losartan study, and 103 from three valsartan studies. DNA was extracted from blood samples and single-nucleotide polymorphisms in the CYP2C8 (CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP2C8*5) and CYP2C9 (CYP2C9*2, CYP2C9*3) genes were evaluated using real-time polymerase chain reaction. Sex only affected telmisartan pharmacokinetics, since women showed a higher telmisartan C(max) than men (590.5 ± 75.8 ng/ml versus 282.1 ± 30.8 ng/ml; P ≤ 0.01). CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3.1 ± 0.4 hours) than in volunteers with the wild-type genotype (2.3 ± 0.1 hours) (P ≤ 0.05). CYP2C8 polymorphisms were associated only with valsartan pharmacokinetics, since *2 allele carriers showed faster clearance (1.07 ± 0.57 l/h·kg) than those with the wild-type genotype (0.48 ± 0.72 l/h·kg; P ≤ 0.01) and carriers of the *3 allele (0.35 ± 0.49 l/h·kg; P ≤ 0.001). These results suggest that genotypes for CYP2C9 and CYP2C8 are relevant to the pharmacokinetics of losartan and valsartan, respectively, but not the pharmacokinetics of candesartan or telmisartan.</abstract><cop>United States</cop><pmid>23118328</pmid><doi>10.1124/dmd.112.046292</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-9556
ispartof Drug metabolism and disposition, 2013-01, Vol.41 (1), p.224-229
issn 0090-9556
1521-009X
language eng
recordid cdi_proquest_miscellaneous_1273402189
source MEDLINE; Alma/SFX Local Collection
subjects Alleles
Angiotensin Receptor Antagonists - pharmacokinetics
Aryl Hydrocarbon Hydroxylases - genetics
Cytochrome P-450 CYP2C8
Cytochrome P-450 CYP2C9
Female
Half-Life
Humans
Male
Polymorphism, Genetic
Reference Values
Sex Factors
title Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A36%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20relationship%20between%20sex,%20polymorphisms%20in%20CYP2C8%20and%20CYP2C9,%20and%20pharmacokinetics%20of%20angiotensin%20receptor%20blockers&rft.jtitle=Drug%20metabolism%20and%20disposition&rft.au=Cabaleiro,%20Teresa&rft.date=2013-01-01&rft.volume=41&rft.issue=1&rft.spage=224&rft.epage=229&rft.pages=224-229&rft.issn=0090-9556&rft.eissn=1521-009X&rft_id=info:doi/10.1124/dmd.112.046292&rft_dat=%3Cproquest_cross%3E1273402189%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273402189&rft_id=info:pmid/23118328&rfr_iscdi=true